Abstract:The World Health Organization has declared that the outbreak of coronavirus disease 2019(COVID-19)is a global pandemic.As mutations occurred in the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the global epidemic still needs further concern.Worryingly,the effectiveness and neutralizing activity of existing antibodies and vaccines against SARS-CoV-2 variants is declining.There is an urgent need to find an effective antiviral medication with broad-spectrum inhibitory effects on novel coronavirus mutant strains against the SARS-CoV-2 infection.Neutralizing antibodies play an important role in the prevention and treatment of COVID-19.The interaction of spike-receptor-binding domain(Spike-RBD)of SARS-CoV-2 and human angiotensin-converting enzyme 2(ACE2)is the first and critical step of SARS-CoV-2 infection.Hence,the SARS-CoV-2 Spike-RBD is a hot target for neutralizing antibodies development.Evusheld,the combination of Tixagevimab and Cilgavimab monoclonal antibodies(mAbs)targeting Spike-RBD exhibits neutralizing activity against BA.2.12.1,BA.4 and BA.5,which could be used as pre-exposure prophylaxis against SARS-CoV-2 infection.The nucleocapsid(N)protein is a conservative and high-abundance structural protein of SARS-CoV-2.The nCoV396 monoclonal antibody,isolated from the blood of convalescent COVID-19 patients against the N protein of SARS-CoV-2.This mAb not only showed neutralizing activity but also inhibits hyperactivation of complement and lung injury induced by N protein.The mAb 3E8 targeting ACE2 showed broadly neutralizing activity against SARS-CoV-2 and D614G,B.1.1.7,B.1.351,B.1.617.1 and P.1 variants in vitro and in vivo,but did not impact the biological activity of ACE2.Compared with neutralizing antibodies,small molecule inhibitors have several advantages,such as broad-spectrum inhibitory effect,low cost,and simple administration methods.Several small-molecule inhibitors disrupt viral binding by targeting the ACE2 and N-terminal domain(NTD)of SARS-CoV-2 spike protein.Known drugs such as chloroquine and hydroxychloroquine could also block the infection of SARS-CoV-2 by interacting with residue Lys353 in the peptidase domain of ACE2.The transmembrane protease serine 2(TMPRSS2)inhibitors Camostat mesylate and Proxalutamide inhibit infection by blocking TMPRSS2 mediates viral membrane fusion.The main protease inhibitor Paxlovid and RNA-dependent RNA polymerase inhibitor Azvudine have been approved for treatment of COVID-19 patients.This review summarizes the current research status of neutralizing antibodies and small molecule inhibitors and prospects for their application.We expect to provide more valuable information for further studies in this field.

Analysis of the molecular mechanism of SARS-CoV-2 antibodies

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies As Promising Therapeutics Against SARS-CoV-2 Infection

The Research Status of Novel Coronavirus Antibodies and Small Molecule Inhibitors

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses

Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective.

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

The development of neutralizing antibodies against SARS-CoV-2 and their common features

Neutralization of SARS-CoV-2 Infection by Antibodies Targeting Diverse Epitopes

Human neutralizing antibodies elicited by SARS-CoV-2 infection

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Review of COVID-19 Antibody Therapies

Neutralizing Monoclonal Antibodies Present New Prospects to Treat SARS-CoV-2 Infections

Computational Approach for Binding Prediction of SARS-CoV-2 with Neutralizing Antibodies

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

A Broadly Neutralizing Antibody Inhibits SARS-CoV-2 Variants Through a Novel Mechanism of Disrupting Spike Trimer Integrity